


CLAIMS

We claim:

1. A compound of Formula (I):



(I)

or a salt, solvate, or physiologically functional derivative thereof:

wherein:

D is $-NRR^1$, $-OR$, $-SR$, $-S(O)R$, or $-S(O)_2R$;

R is hydrogen, C_1 - C_8 alkyl, C_3 - C_7 cycloalkyl, aralkyl, aryl, heteroaryl, $-C(O)NR^1R^1$, $-C(O)OR^1$, acyl, aroyl, or heteroaroyl;

R^1 is hydrogen, C_1 - C_8 alkyl, C_3 - C_7 cycloalkyl, aralkyl, or aryl;

R^2 is C_1 - C_6 alkyl or C_3 - C_7 cycloalkyl;

R^3 is hydrogen, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, aralkyl, cyanoalkyl, $-(CH_2)_pC=CH(CH_2)_tH$, $-(CH_2)_pC\equiv C(CH_2)_tH$, or C_3 - C_7 cycloalkyl;

p is 1, 2, or 3;

t is 0 or 1;

R^4 is hydrogen, halo, or cyano;

Q_1 is hydrogen, halo, C_1 - C_2 haloalkyl, C_1 - C_2 alkyl, C_1 - C_2 alkoxy, or C_1 - C_2 haloalkoxy;

Q_2 is A^1 or A^2 ;

Q_3 is A^1 when Q_2 is A^2 and Q_3 is A^2 when Q_2 is A^1 ;

wherein

A¹ is hydrogen, halo, C₁-C₃ alkyl, C₁-C₃ haloalkyl, -OR⁵, and

A² is the group defined by -(Z)_m-(Z¹)-(Z²), wherein

Z is CH₂ and m is 0, 1, 2, or 3, or

Z is NR⁵ and m is 0 or 1, or

Z is oxygen and m is 0 or 1, or

Z is CH₂NR⁶ and m is 0 or 1;

Z¹ is S(O)₂, S(O), or C(O); and

Z² is C₁-C₄ alkyl, cycloalkyl, heterocyclyl, -NR⁸R⁹, aryl, arylamino, aralkyl, aralkoxy, or heteroaryl;


R⁵ and R⁶ are each independently selected from hydrogen, hydroxyl, alkoxy, aryloxy, aralkoxy, C₁-C₄ alkyl, C₃-C₇ cycloalkyl, heterocyclyl, -S(O)₂R⁷, and -C(O)R⁷;

R⁷ is C₁-C₄ alkyl, or C₃-C₇ cycloalkyl;

R⁸ is hydrogen, hydroxyl, C₁-C₆ alkyl, C₁-C₆ alkoxy, aryloxy, aralkoxy, C₃-C₇ cycloalkyl, and C₃-C₇ cycloalkoxy; and

R⁹ is hydrogen, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, aryl, acyl, carbamoyl, or heterocyclyl.

2. A compound of Formula (II):



(II)

or a salt, solvate, or physiologically functional derivative thereof:

wherein:

R is hydrogen, C₁-C₈ alkyl, C₃-C₇ cycloalkyl, aralkyl, aryl, heteroaryl, -C(O)NR¹R¹, -C(O)OR¹, acyl, aroyl, or heteroaroyl;

R¹ is hydrogen, C₁-C₈ alkyl, C₃-C₇ cycloalkyl, aralkyl, or aryl;

R^2 is C_1 - C_6 alkyl or C_3 - C_7 cycloalkyl;

R^3 is hydrogen, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, aralkyl, cyanoalkyl,

$-(CH_2)_pC=CH(CH_2)_tH$, $-(CH_2)_pC\equiv C(CH_2)_tH$, or C_3 - C_7 cycloalkyl;

p is 1, 2, or 3;

t is 0 or 1;

R^4 is hydrogen, halo, or cyano;

Q_1 is hydrogen, halo, C_1 - C_2 haloalkyl, C_1 - C_2 alkyl, C_1 - C_2 alkoxy, or C_1 - C_2 haloalkoxy;

Q_2 is A^1 or A^2 ;

Q_3 is A^1 when Q_2 is A^2 and Q_3 is A^2 when Q_2 is A^1 ;

wherein

A^1 is hydrogen, halo, C_1 - C_3 alkyl, C_1 - C_3 haloalkyl, $-OR^5$, and

A^2 is the group defined by $-(Z)_m-(Z^1)-(Z^2)$, wherein

Z is CH_2 and m is 0, 1, 2, or 3, or

Z is NR^5 and m is 0 or 1, or

Z is oxygen and m is 0 or 1, or

Z is CH_2NR^6 and m is 0 or 1;

Z^1 is $S(O)_2$, $S(O)$, or $C(O)$; and

Z^2 is C_1 - C_4 alkyl, cycloalkyl, heterocyclyl, $-NR^8R^9$, aryl, arylamino, aralkyl, aralkoxy, or heteroaryl;

R^5 and R^6 are each independently selected from hydrogen, hydroxyl, alkoxy, aryloxy, aralkoxy, C_1 - C_4 alkyl, C_3 - C_7 cycloalkyl, heterocyclyl, $-S(O)_2R^7$, or $-C(O)R^7$;

R^7 is C_1 - C_4 alkyl, or C_3 - C_7 cycloalkyl;

R^8 is hydrogen, hydroxyl, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, aryloxy, aralkoxy, C_3 - C_7 cycloalkyl, or C_3 - C_7 cycloalkoxy; and

R^9 is hydrogen, C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, aryl, acyl, carbamoyl, or heterocyclyl.

3. A compound as claimed in claim 1, wherein D is $-NRR^1$.

4. A compound as claimed in claim 1, wherein D is $-NRR^1$ and R is C_1-C_8 alkyl, aryl, or aralkyl and R^1 is hydrogen.
5. A compound as claimed in claim 1, wherein D is $-NRR^1$, wherein R is methyl, isopropyl, benzyl, or phenyl and R^1 is hydrogen.
6. A compound as claimed in claim 1 or 2, wherein R^2 is C_1-C_8 alkyl
7. A compound as claimed in claim 1 or 2, wherein R^2 is methyl.
8. A compound as claimed in claim 1 or 2, wherein In one embodiment, R^3 is hydrogen, C_1-C_4 alkyl, cyanoalkyl, or $-(CH_2)_pC\equiv C(CH_2)_tH$.
9. A compound as claimed in claim 1 or 2, wherein, R^3 is hydrogen, methyl, ethyl, isopropyl, cyanomethyl, or $-(CH_2)_pC\equiv C(CH_2)_tH$, wherein p is 1 and t is 0.
10. A compound as claimed in claim 1 or 2, wherein R^3 is methyl.
11. A compound as claimed in claim 1 or 2, wherein R^4 is hydrogen or halo.
12. A compound as claimed in claim 1 or 2, wherein In a preferred embodiment, R^4 is hydrogen.
13. A compound as claimed in claim 1 or 2, wherein Q_1 is hydrogen, halo, C_1-C_2 alkyl or C_1-C_2 alkoxy.
14. A compound as claimed in claim 1 or 2, wherein Q_1 is hydrogen, chloro, methyl, or methoxy.
15. A compound as claimed in claim 1 or 2, wherein Q_2 is A^1 and Q_3 is A^2 .
16. A compound as claimed in claim 1 or 2, wherein Q_2 is A^2 and Q_3 is A^1 .

17. A compound as claimed in claim 1 or 2, wherein Q_2 is A^2 and Q_3 is A^1 , wherein A^1 is hydrogen, halo, or C_1 - C_3 haloalkyl and A^2 is the group defined by $-(Z)_m-(Z^1)-(Z^2)$, wherein Z is CH_2 and m is 0 or 1; Z^1 is $S(O)_2$; and Z^2 is C_1 - C_4 alkyl or NR^8R^9 and wherein R^8 is hydrogen C_1 - C_4 alkyl, or alkoxy and R^9 is hydrogen, C_1 - C_4 alkyl, or alkoxy.

18. A compound as claimed in claim 1 or 2, wherein Q_2 is A^2 and Q_3 is A^1 , wherein A^1 is hydrogen or chloro and A^2 is the group defined by $-(Z)_m-(Z^1)-(Z^2)$, wherein Z is CH_2 and m is 0 or 1; Z^1 is $S(O)_2$; and Z^2 is methyl or $-NH_2$.

19. A compound as claimed in claim 1 or 2, wherein Q_2 is A^1 and Q_3 is A^2 , wherein A^1 is hydrogen, halo, or C_1 - C_3 alkyl and A^2 is the group defined by $-(Z)_m-(Z^1)-(Z^2)$, wherein Z is CH_2 and m is 0 or 1; Z^1 is $S(O)_2$; and Z^2 is C_1 - C_4 alkyl or NR^8R^9 , and wherein R^8 is hydrogen C_1 - C_4 alkyl, or alkoxy and R^9 is hydrogen, C_1 - C_4 alkyl, or alkoxy.

20. A compound as claimed in claim 1 or 2, wherein Q_2 is A^1 and Q_3 is A^2 , wherein A^1 is hydrogen, methyl, or chloro and A^2 is the group defined by $-(Z)_m-(Z^1)-(Z^2)$, wherein Z is CH_2 and m is 0 or 1; Z^1 is $S(O)_2$; and Z^2 is NR^8R^9 , wherein R^8 is methoxy and R^9 is hydrogen.

21. A compound as claimed in claim 1, wherein, D is $-NRR^1$, where R is C_1 - C_8 alkyl, aryl, or aralkyl and R^1 is hydrogen; R^2 is C_1 - C_8 alkyl. R^2 is methyl; R^3 is methyl; R^4 is hydrogen; Q_1 is hydrogen, chloro, methyl, or methoxy; Q_2 is A^2 and Q_3 is A^1 , where A^1 is hydrogen or chloro and A^2 is the group defined by $-(Z)_m-(Z^1)-(Z^2)$, where Z is CH_2 and m is 0 or 1; Z^1 is $S(O)_2$; and Z^2 is methyl or $-NH_2$.

22. A compound as claimed in claim 1, wherein D is $-NRR^1$, where R is C_1 - C_8 alkyl, aryl, or aralkyl and R^1 is hydrogen; R^2 is C_1 - C_8 alkyl. R^2 is methyl; R^3 is methyl; R^4 is hydrogen; Q_1 is hydrogen, chloro, methyl, or methoxy; Q_2 is A^1 and Q_3 is A^2 , where A^1 is hydrogen, methyl, or chloro and A^2 is the group defined by $-(Z)_m-(Z^1)-(Z^2)$, where Z is CH_2 and m is 0 or 1; Z^1 is $S(O)_2$; and Z^2 is NR^8R^9 , where R^8 is methoxy and R^9 is hydrogen.

23. A compound as claimed in claim 1, selected from the group consisting of:

*N*²-isopropyl-*N*⁵,1-dimethyl-*N*⁶-[2-({4-[(methylsulfonyl)methyl]phenyl} amino)pyrimidin-4-yl]-1*H*-benzimidazole-2,5-diamine;

*N*²-isopropyl-*N*⁵,1-dimethyl-*N*⁶-[2-({4-[(methylsulfonyl)methyl]phenyl} amino)pyrimidin-4-yl]-1*H*-benzimidazole-2,5-diamine;

1-{4-[(4-{methyl[1-methyl-2-(methylamino)-1*H*-benzimidazol-5-yl]amino}pyrimidin-2-yl)amino]phenyl}methanesulfonamide;

*N*²-benzyl-*N*⁵,1-dimethyl-*N*⁶-[2-({4-[(methylsulfonyl)methyl]phenyl} amino)pyrimidin-4-yl]-1*H*-benzimidazole-2,5-diamine;

*N*⁵,1-dimethyl-*N*⁶-[2-({4-[(methylsulfonyl)methyl]phenyl} amino)pyrimidin-4-yl]-*N*²-phenyl-1*H*-benzimidazole-2,5-diamine; and

5-({4-[(2-(benzylamino)-1-methyl-1*H*-benzimidazol-5-yl)(methyl)amino]pyrimidin-2-yl} amino)-*N*-methoxy-2-methylbenzenesulfonamide;

or a salt, solvate, or physiologically functional derivative thereof.

24. A compound as claimed in claim 1, selected from the group:

3-{4-[(2-benzylamino-1-methyl-1*H*-benzimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-benzenesulfonamide;

5-{4-[(2-benzylamino-1-methyl-1*H*-benzimidazol-5-yl)-methyl-amino]-pyrimidinylamino}-2-methyl-benzenesulfonamide;

(4-{4-[(2-benzylamino-1-methyl-1*H*-benzimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-phenyl)-methanesulfonamide;

2-(4-{4-[(2-benzylamino-1-methyl-1*H*-benzimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-phenyl)-ethanesulfonic acid methylamide;

3-(4-{[2-(4-fluoro-benzylamino)-1-methyl-1*H*-benzimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-benzenesulfonamide;

5-(4-{[2-(4-fluoro-benzylamino)-1-methyl-1*H*-benzimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-2-methyl-benzenesulfonamide;

*N*²-(4-fluoro-benzyl)-*N*⁶-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, *N*⁶-dimethyl-1H-benzoimidazole-2,5-diamine;

[4-(4-{[2-(4-fluoro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-phenyl]-methanesulfonamide;

2-[4-(4-{[2-(4-fluoro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-phenyl]-ethanesulfonic acid methylamide;

3-(4-{[2-(4-methoxy-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-benzenesulfonamide;

5-(4-{[2-(4-methoxy-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-2-methyl-benzenesulfonamide;

*N*⁶-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-*N*²-(4-methoxy-benzyl)-1, *N*⁶-dimethyl-1H-benzoimidazole-2,5-diamine;

[4-(4-{[2-(4-methoxy-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-phenyl]-methanesulfonamide;

2-[4-(4-{[2-(4-methoxy-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-phenyl]-ethanesulfonic acid methylamide;

5-(4-{[2-(3-fluoro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-2-methyl-benzenesulfonamide;

3-(4-{[2-(3-fluoro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-benzenesulfonamide;

*N*²-(3-fluoro-benzyl)-*N*⁶-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, *N*⁶-dimethyl-1H-benzoimidazole-2,5-diamine;

[4-(4-{[2-(3-fluoro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-phenyl]-methanesulfonamide;

2-[4-(4-{[2-(3-fluoro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-phenyl]-ethanesulfonic acid methylamide;

3-(4-{[2-(4-chloro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-benzenesulfonamide;

5-(4-{[2-(4-chloro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-2-methyl-benzenesulfonamide;

2-[4-(4-{[2-(4-chloro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-phenyl]-ethanesulfonic acid methylamide;

*N*²-(4-chloro-benzyl)-*N*⁵-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, *N*⁵-dimethyl-1H-benzoimidazole-2,5-diamine;

3-{4-[(2-benzylamino-1-ethyl-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-benzenesulfonamide;

5-{4-[(2-benzylamino-1-ethyl-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-2-methyl-benzenesulfonamide;

*N*²-benzyl-1-ethyl-*N*⁵-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-*N*⁵-methyl-1H-benzoimidazole-2,5-diamine;

(4-{4-[(2-benzylamino-1-ethyl-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-phenyl)-methanesulfonamide;

3-(4-{2-(2-fluoro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylmethyl)-benzenesulfonamide;

5-(4-{2-(2-fluoro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-2-methyl-benzenesulfonamide;

[4-(4-{2-(2-fluoro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-phenyl]-methanesulfonamide;

2-(4-{4-[(2-benzylamino-1-ethyl-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-phenyl)-ethanesulfonic acid methylamide;

3-(4-{methyl-[1-methyl-2-(1-phenyl-ethylamino)-1H-benzoimidazol-5-yl]-amino}-pyrimidin-2-ylamino)-benzenesulfonamide;

2-methyl-5-(4-{methyl-[1-methyl-2-(1-phenyl-ethylamino)-1H-benzoimidazol-5-yl]-amino}-pyrimidin-2-ylamino)-benzenesulfonamide;

*N*⁵-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, *N*⁵-dimethyl-*N*²-(1-phenyl-ethyl)-1H-benzoimidazole-2,5-diamine;

[4-(4-{methyl-[1-methyl-2-(1-phenyl-ethylamino)-1H-benzoimidazol-5-yl]-amino}-pyrimidin-2-ylamino)-phenyl]-methanesulfonamide;

3-(4-{2-(3-chloro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-benzenesulfonamide;

3-(4-{2-(3-chloro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-benzenesulfonamide;

[4-(4-{2-(4-chloro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-phenyl]-methanesulfonamide;

methanesulfonic acid-3-(4-{[2-(4-chloro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-phenyl ester;

N^5 -{2-[4-(2-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl}- N^2 -(4-methoxybenzyl)-1, N^5 -dimethyl-1H-benzoimidazole-2,5-diamine;

N^5 -{2-[3-(2-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl}- N^2 -(4-methoxybenzyl)-1, N^5 -dimethyl-1H-benzoimidazole-2,5-diamine;

N^5 -{2-[4-(1-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl}- N^2 -(4-methoxybenzyl)-1, N^5 -dimethyl-1H-benzoimidazole-2,5-diamine;

N^5 -[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]- N^2 -(4-methoxybenzyl)-1, N^5 -dimethyl-1H-benzoimidazole-2,5-diamine;

N^2 -benzyl- N^5 -[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, N^5 -dimethyl-1H-benzoimidazole-2,5-diamine;

N^5 -[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, N^5 -dimethyl- N^2 -(1-phenyl-ethyl)-1H-benzoimidazole-2,5-diamine;

N^5 -{2-[3-(2-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl}-1, N^5 -dimethyl- N^2 -(1-phenyl-ethyl)-1H-benzoimidazole-2,5-diamine;

N^5 -{2-[4-(2-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl}-1, N^5 -dimethyl- N^2 -(1-phenyl-ethyl)-1H-benzoimidazole-2,5-diamine;

2-methyl-5-(4-{methyl-[1-methyl-2-(4-methyl-benzylamino)-1H-benzoimidazol-5-yl]-amino}-pyrimidin-2-ylamino)-benzenesulfonamide;

N^5 -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, N^5 -dimethyl- N^2 -(4-methyl-benzyl)-1H-benzoimidazole-2,5-diamine;

N^5 -[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, N^5 -dimethyl- N^2 -(4-methyl-benzyl)-1H-benzoimidazole-2,5-diamine;

N^5 -{2-[4-(2-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl}-1, N^5 -dimethyl- N^2 -(4-methyl-benzyl)-1H-benzoimidazole-2,5-diamine;

N^5 -{2-[3-(2-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl}-1, N^5 -dimethyl- N^2 -(4-methyl-benzyl)-1H-benzoimidazole-2,5-diamine; and

N^5 -{2-[4-(1-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl}-1, N^5 -dimethyl- N^2 -(4-methyl-benzyl)-1H-benzoimidazole-2,5-diamine;

or a salt, solvate, or physiologically functional derivative thereof.

25. A compound as claimed in claim 1, selected from the group:

(1-methyl-5-{methyl-[2-(3-sulfamoyl-phenylamino)-pyrimidin-4-yl]-amino}-1H-benzimidazol-2-yl)-phenyl-carbamic acid tert-butyl ester;

3-{4-[methyl-(1-methyl-2-phenylamino-1H-benzimidazol-5-yl)-amino]-pyrimidin-2-ylamino}-benzenesulfonamide;

(1-methyl-5-{methyl-[2-(4-methyl-3-sulfamoyl-phenylamino)-pyrimidin-4-yl]-amino}-1H-benzimidazol-2-yl)-phenyl-carbamic acid tert-butyl ester;

*N*⁶-[2-(3-methanesulfonyl-4-methyl-phenylamino)-pyrimidin-4-yl]-1, *N*⁶-dimethyl-*N*²-phenyl-1H-benzimidazole-2,5-diamine;

*N*⁶-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, *N*⁶-dimethyl-*N*²-phenyl-1H-benzimidazole-2,5-diamine;

(4-{4-[methyl-(1-methyl-2-phenylamino-1H-benzimidazol-5-yl)-amino]-pyrimidin-2-ylamino}-phenyl)-methanesulfonamide;

methanesulfonic acid 4-{4-[methyl-(1-methyl-2-phenylamino-1H-benzimidazol-5-yl)-amino]-pyrimidin-2-ylamino}-phenyl ester;

3-(4-{[2-(4-fluoro-phenylamino)-1-methyl-1H-benzimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-benzenesulfonamide;

5-(4-{[2-(4-fluoro-phenylamino)-1-methyl-1H-benzimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-2-methyl-benzenesulfonamide;

*N*²-(4-fluoro-phenyl)-*N*⁶-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, *N*⁶-dimethyl-1H-benzimidazole-2,5-diamine;

[4-(4-{[2-(4-fluoro-phenylamino)-1-methyl-1H-benzimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-phenyl]-methanesulfonamide;

methanesulfonic acid 4-(4-{[2-(4-fluoro-phenylamino)-1-methyl-1H-benzimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-phenyl ester;

methanesulfonic acid 3-(4-{[2-(4-fluoro-phenylamino)-1-methyl-1H-benzimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-phenyl ester;

*N*⁶-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, *N*⁶-dimethyl-*N*²-p-tolyl-1H-benzimidazole-2,5-diamine;

[4-(4-{[2-(4-tert-butyl-phenylamino)-1-methyl-1H-benzimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-phenyl]-methanesulfonamide;

3-(4-{[2-(4-tert-butyl-phenylamino)-1-methyl-1H-benzimidazol-5-yl]-me

thyl-amino}-pyrimidin-2-ylamino)-benzenesulfonamide;

5-(4-{[2-(4-tert-butyl-phenylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-2-methyl-benzenesulfonamide;

*N*²-(4-tert-butyl-phenyl)-*N*⁶-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, *N*⁶-dimethyl-1H-benzoimidazole-2,5-diamine;

(5-{[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-1-methyl-1H-benzoimidazol-2-yl)-(4-methoxy-phenyl)-carbamic acid tert-butyl ester;

*N*⁶-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-*N*²-(4-methoxy-phenyl)-1, *N*⁶-dimethyl-1H-benzoimidazole-2,5-diamine;

(4-methoxy-phenyl)-(1-methyl-5-{methyl-[2-(4-sulfamoylmethyl-phenylamino)-pyrimidin-4-yl]-amino}-1H-benzoimidazol-2-yl)-carbamic acid tert-butyl ester;

[4-(4-{[2-(4-methoxy-phenylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-phenyl]-methanesulfonamide;

(5-{[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-1-methyl-1H-benzoimidazol-2-yl)-(4-methoxy-phenyl)-carbamic acid tert-butyl ester;

*N*⁶-[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-*N*²-(4-methoxy-phenyl)-1, *N*⁶-dimethyl-1H-benzoimidazole-2,5-diamine;

[5-{[2-[4-(1-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl]-methyl-amino}-1-methyl-1H-benzoimidazol-2-yl)-(4-methoxy-phenyl)-carbamic acid tert-butyl ester;

*N*⁶-{2-[4-(1-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl}-*N*²-(4-methoxy-phenyl)-1, *N*⁶-dimethyl-1H-benzoimidazole-2,5-diamine; and

*N*⁶-{2-[3-(1-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl}-*N*²-(4-methoxy-phenyl)-1, *N*⁶-dimethyl-1H-benzoimidazole-2,5-diamine;

or a salt, solvate, or physiologically functional derivative thereof.

26. A compound as claimed in claim 1, selected from the group:

3-{4-[(2-isopropylamino-1-methyl-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-benzenesulfonamide;

2-chloro-5-{4-[(2-isopropylamino-1-methyl-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-benzenesulfonamide;

5-{4-[(2-isopropylamino-1-methyl-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-2-methyl-benzenesulfonamide;

2-(4-{4-[(2-isopropylamino-1-methyl-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-phenyl)-ethanesulfonic acid methylamide;

methanesulfonic acid 4-{4-[(2-isopropylamino-1-methyl-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-phenyl ester;

methanesulfonic acid 3-{4-[(2-isopropylamino-1-methyl-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-phenyl ester;

*N*²-isopropyl-*N*⁵-[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, *N*⁵-dimethyl-1H-benzoimidazole-2,5-diamine;

3-[4-(1-methyl-2-phenethylamino-1H-benzoimidazol-5-ylamino)-pyrimidin-2-ylamino]-benzenesulfonamide;

2-methyl-5-{4-[methyl-(1-methyl-2-phenethylamino-1H-benzoimidazol-5-yl)-amino]-pyrimidin-2-ylamino}-benzenesulfonamide;

(4-{4-[methyl-(1-methyl-2-phenethylamino-1H-benzoimidazol-5-yl)-amino]-pyrimidin-2-ylamino}-phenyl)-methanesulfonamide;

*N*⁵-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, *N*⁵-dimethyl-*N*²-phenethyl-1H-benzoimidazole-2,5-diamine;

2-(4-{4-[methyl-(1-methyl-2-phenethylamino-1H-benzoimidazol-5-yl)-amino]-pyrimidin-2-ylamino}-phenyl)-ethanesulfonic acid methylamide;

*N*²-tert-Butyl-*N*⁵-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, *N*⁵-dimethyl-1H-benzoimidazole-2,5-diamine;

*N*²-cyclohexyl-*N*⁵-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, *N*⁵-dimethyl-1H-benzoimidazole-2,5-diamine;

5-{4-[(2-cyclohexylamino-1-methyl-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-2-methyl-benzenesulfonamide;

*N*²-cyclohexyl-*N*⁵-{2-[3-(2-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl}-1, *N*⁵-dimethyl-1H-benzoimidazole-2,5-diamine;

*N*²-cyclohexyl-*N*⁵-{2-[4-(2-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl}-1, *N*⁵-dimethyl-1H-benzoimidazole-2,5-diamine;

*N*²-cyclohexyl-*N*⁵-{2-[4-(1-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl}-1, *N*⁵-dimethyl-1H-benzoimidazole-2,5-diamine;

2-methyl-5-{4-[methyl-(1-methyl-2-methylamino-1H-benzoimidazol-5-yl)-amino]-pyrimidin-2-ylamino}-benzenesulfonamide;

(4-{4-[methyl-(1-methyl-2-methylamino-1H-benzoimidazol-5-yl)-amino]-pyrimidin-2-ylamino}-phenyl)-methanesulfonamide;

3-{4-[methyl-(1-methyl-2-methylamino-1H-benzoimidazol-5-yl)-amino]-pyrimidin-2-ylamino}-benzenesulfonamide;

*N*⁵-[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, *N*², *N*⁵-trimethyl-1H-benzoimidazole-2,5-diamine; and

(4-{4-[(1-ethyl-2-methylamino-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-phenyl)-methanesulfonamide;

or a salt, solvate, or physiologically functional derivative thereof.

27. A compound as claimed in claim 1, selected from the group:

*N*¹-methyl-*N*⁵-[2-(4-Methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-*N*⁵-methyl-*N*²-(4-trifluoromethyl-phenyl)-1H-benzoimidazole-2,5-diamine;

*N*²-(3-chloro-phenyl)-*N*⁵-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-*N*¹,*N*⁵-dimethyl-1H-benzoimidazole-2,5-diamine;

*N*²-(4-chloro-phenyl)-*N*⁵-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-*N*¹,*N*⁵-dimethyl-1H-benzoimidazole-2,5-diamine;

*N*²-(2,4-dichloro-phenyl)-*N*⁵-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-*N*¹,*N*⁵-dimethyl-1H-benzoimidazole-2,5-diamine;

*N*²-(2,5-dichloro-phenyl)-*N*⁵-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-*N*¹,*N*⁵-dimethyl-1H-benzoimidazole-2,5-diamine;

*N*²-(2-chloro-4-trifluoromethyl-phenyl)-*N*⁵-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-*N*¹,*N*⁵-dimethyl-1H-benzoimidazole-2,5-diamine;

*N*²-(2-chloro-5-trifluoromethyl-phenyl)-*N*⁵-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-*N*¹,*N*⁵-dimethyl-1H-benzoimidazole-2,5-diamine;

*N*⁵-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-*N*¹,*N*⁵-dimethyl-*N*²-(4-morpholin-4-yl-phenyl)-1H-benzoimidazole-2,5-diamine;

*N*²-(3-fluoro-phenyl)-*N*⁵-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-*N*¹,*N*⁵-dimethyl-1H-benzoimidazole-2,5-diamine;

*N*²-(2,4-difluoro-phenyl)-*N*⁵-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-*N*¹,*N*⁵-dimethyl-1H-benzoimidazole-2,5-diamine;

N^2 -(2-chloro-4-fluoro-phenyl)- N^5 -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]- N^1,N^5 -dimethyl-1H-benzimidazole-2,5-diamine;

N^2 -(4-chloro-2-fluoro-phenyl)- N^5 -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]- N^1,N^5 -dimethyl-1H-benzimidazole-2,5-diamine;

N^2 -(2-chloro-5-fluoro-phenyl)- N^5 -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]- N^1,N^5 -dimethyl-1H-benzimidazole-2,5-diamine;

N^2 -(2-fluoro-4-methyl-phenyl)- N^5 -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]- N^1,N^5 -dimethyl-1H-benzimidazole-2,5-diamine;

N^2 -(2-fluoro-phenyl)- N^5 -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]- N^1,N^5 -dimethyl-1H-benzimidazole-2,5-diamine;

N^2 -(2-fluoro-5-trifluoromethyl-phenyl)- N^5 -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]- N^1,N^5 -dimethyl-1H-benzimidazole-2,5-diamine;

4-{4-[methyl-(1-methyl-2-methylsulfonyl-1H-benzimidazol-5-yl)-amino]-pyrimidin-2-ylamino}-benzene sulfonamide;

4-{4-[(2-methanesulfinyl-1-methyl-1H-benzimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-benzenesulfonamide;

4-(4-{methyl-[1-methyl-2-(4-trifluoromethyl-phenylamino)-1H-benzimidazol-5-yl]-amino}-pyrimidin-2-ylamino)-benzenesulfonamide;

(methyl-nitro-1H-benzimidazol-2-yl)-(3-trifluoromethyl-phenyl)-amine;

(methyl-nitro-1H-benzimidazol-2-yl)-(3-trifluoromethyl-phenyl)-carbamic acid dimethyl-ethyl ester;

(amino-methyl-1-benzimidazol-2-yl)-(3-trifluoromethyl-phenyl)-carbamic acid dimethyl-ethyl ester;

[(2-chloro-pyrimidin-4-yl)-methyl-amino]-methyl-1H-benzimidazol-2-yl-(3-trifluoromethyl-phenyl)-carbamic acid dimethyl-ethyl ester; and

N^5 -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]- N^1,N^5 -dimethyl- N^2 -(3-trifluoromethyl-phenyl)-1H-benzimidazole-2,5-diamine;

or a salt, solvate, or physiologically functional derivative thereof.

28. A compound as claimed in claim 1, selected from the group:

N^2 -(5-tert-butyl-isoxazol-3-yl)- N^5 -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, N^5 -dimethyl-1H-methyl-amino-benzimidazole-2,5-diamine;

*N*²-(5-tert-butyl-isoxazol-3-yl)-*N*⁵-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1-methyl-1H-benzoimidazole-2,5-diamine;

*N*²-(5-tert-butyl-isoxazol-3-yl)-*N*⁵-[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1-methyl-1H-benzoimidazole-2,5-diamine;

*N*²-(5-tert-butyl-isoxazol-3-yl)-*N*⁵-[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, *N*⁵-dimethyl-1H-benzoimidazole-2,5-diamine;

*N*²-(5-tert-butyl-isoxazol-3-yl)-*N*⁵-[2-(3-methanesulfonyl-4-methyl-phenylamino)-pyrimidin-4-yl]-1-methyl-1H-benzoimidazole-2,5-diamine;

5-(4-{[2-(5-tert-butyl-isoxazol-3-ylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-2-methyl-benzenesulfonamide;

*N*²-(6-fluoro-4H benzo[1,3]dioxin-8-ylmethyl)-*N*⁵-[2-(3-methanesulfonyl-4-methyl-phenylamino)-pyrimidin-4-yl]-1-methyl-1H-benzoimidazole-2,5-diamine; and

*N*²-(5-tert-butyl-isoxazol-3-yl)-1-methyl-*N*⁵-[2-[3-(morpholine-4-sulfonyl)-phenylamino]-pyrimidin-4-yl]-1H-benzoimidazole-2,5-diamine;

or a salt, solvate, or physiologically functional derivative thereof.

29. A compound as claimed in claim 1, selected from the group:

N-(1-methyl-5-{methyl[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-1H-benzimidazol-2-yl)-*N'*-phenylurea;

N-(1-methyl-5-{methyl[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-1H-benzimidazol-2-yl)benzamide;

N-(1-methyl-5-{methyl[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-1H-benzimidazol-2-yl)indoline-1-carboxamide;

N-(5-tert-butylisoxazol-3-yl)-*N'*-(1-methyl-5-{methyl[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-1H-benzimidazol-2-yl)urea;

N-(1-methyl-5-{methyl[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-1H-benzimidazol-2-yl)-2-phenylacetamide;

N-(1-methyl-5-{methyl[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-1H-benzimidazol-2-yl)-1-phenylcyclopropanecarboxamide;

N-(1-methyl-5-{methyl[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-1H-benzimidazol-2-yl)isonicotinamide;

N-(1-methyl-5-{methyl[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-1H-benzimidazol-2-yl)cyclohexanecarboxamide;

2-(benzyloxy)-*N*-(1-methyl-5-{methyl[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-1H-benzimidazol-2-yl)acetamide;

2-(3-methylisoxazol-5-yl)-*N*-(1-methyl-5-{methyl[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-1H-benzimidazol-2-yl)acetamide; and

3-[(dimethylamino)methyl]-*N*-(1-methyl-5-{methyl[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-1H-benzimidazol-2-yl)benzamide;

or a salt, solvate, or physiologically functional derivative thereof.

30. A compound as claimed in claim 1, selected from the group:

N-({[3-(4-methanesulfonylmethyl-phenylamino)-phenyl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-C-thiophen-2-yl-acetamide;

C-fluoro-*N*-({[3-(3-methanesulfonylmethyl-phenylamino)-phenyl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-trifluoromethyl-benzamide;

difluoro-*N*-({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-benzamide;

N-({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-3,5-bis-trifluoromethyl-benzamide;

cyclohexanecarboxylic acid ({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

N-({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-methyl-benzamide;

N-({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-4-methoxy-benzamide;

C-(chloro-trifluoromethyl-phenyl)-*N*-({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-acetamide;

(3,5-bis-trifluoromethyl-phenyl)-*N*-({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-acetamide;

N-(5-{[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-1-methyl-1H-benzoimidazol-2-yl)-2-(3-trifluoromethylsulfonyl-phenyl)-acetamide;

(2,4-bis-trifluoromethyl-phenyl)-*N*-({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-acetamide;

(2-fluoro-5-trifluoromethyl-phenyl)-*N*-({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-acetamide;

3H-benzotriazole-5-carboxylic acid ({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

3H-benzoimidazole-5-carboxylic acid ({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

thiophene-2-carboxylic acid ({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

thiophene-3-carboxylic acid ({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

N-({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-C-thiophen-2-yl-acetamide;

3-methyl-thiophene-2-carboxylic acid ({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

furan-3-carboxylic acid ({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

3-methyl-furan-2-carboxylic acid ({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

N-({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-2-(3-methyl-isoxazol-5-yl)-acetamide;

C-(chloro-trifluoromethyl-phenyl)-*N*-({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-acetamide;

N-(5-{[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-1-methyl-1H-benzoimidazol-2-yl)-2-(3-trifluoromethylsulfonyl-phenyl)-acetamide;

C-(fluoro-trifluoromethyl-phenyl)-*N*-({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-acetamide;

N-({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-dimethyl-butylamide;

2-propyl-pentanoic acid ({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

N-({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-isobutylamide;

cyclopropanecarboxylic acid ({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

N-({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-4-methoxy-benzamide;

4-methoxy-*N*-(methyl-{methyl-[2-(4-methyl-3-sulfamoyl-phenylamino)-pyrimidin-4-yl]-amino}-1H-benzoimidazol-2-yl)-benzamide;

furan-2-carboxylic acid ({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

N-(methyl-{methyl-[2-(4-methyl-3-sulfamoyl-phenylamino)-pyrimidin-4-yl]-amino}-1H-benzoimidazol-2-yl)-C-thiophen-2-yl-acetamide;

C-(chloro-trifluoromethyl-phenyl)-*N*-(methyl-{methyl-[2-(4-methyl-3-sulfamoyl-phenylamino)-pyrimidin-4-yl]-amino}-1H-benzoimidazol-2-yl)-acetamide;

4-methoxy-*N*-[methyl-(methyl-{2-[3-(morpholine-4-sulfonyl)-phenylamino]-pyrimidin-4-yl}-amino)-1H-benzoimidazol-2-yl]-benzamide;

N-[methyl-(methyl-{2-[3-(morpholine-4-sulfonyl)-phenylamino]-pyrimidin-4-yl}-amino)-1H-benzoimidazol-2-yl]-C-thiophen-2-yl-acetamide;

thiophene-2-carboxylic acid [methyl-(methyl-{2-[3-(morpholine-4-sulfonyl)-phenylamino]-pyrimidin-4-yl}-amino)-1H-benzoimidazol-2-yl]-amide;

furan-2-carboxylic acid [methyl-(methyl-{2-[3-(morpholine-4-sulfonyl)-phenylamino]-pyrimidin-4-yl}-amino)-1H-benzoimidazol-2-yl]-amide;

N-({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-2-(3-methyl-isoxazol-5-yl)-acetamide;

furan-2-carboxylic acid ({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

2-(3-methyl-isoxazol-5-yl)-*N*-[methyl-(methyl-{2-[3-(morpholine-4-sulfonyl)-phenylamino]-pyrimidin-4-yl}-amino)-1H-benzoimidazol-2-yl]-acetamide;

3-methyl-furan-2-carboxylic acid ({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

N-[methyl-(methyl-{2-[3-(4-methyl-piperazine-1-sulfonyl)-phenylamino]-pyrimidin-4-yl}-amino)-1H-benzoimidazol-2-yl]-C-thiophen-2-yl-acetamide;

thiophene-2-carboxylic acid [methyl-(methyl-{2-[3-(4-methyl-piperazine-1-sulfonyl)-phenylamino]-pyrimidin-4-yl}-amino)-1H-benzoimidazol-2-yl]-amide;

furan-2-carboxylic acid [methyl-(methyl-{2-[3-(4-methyl-piperazine-1-sulfonyl)-phenylamino]-pyrimidin-4-yl}-amino)-1H-benzoimidazol-2-yl]-amide;

2-(3-methyl-isoxazol-5-yl)-*N*-[methyl-(methyl-{2-[3-(4-methyl-piperazine-1-sulfonyl)-phenylamino]-pyrimidin-4-yl}-amino)-1H-benzoimidazol-2-yl]-acetamide;

N-({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-dimethyl-butamide;

N-({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-propionamide;

pentanoic acid ({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

N-({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-butamide;

phenyl- *N*-({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-acetamide;

phenylcyclopropanecarboxylic acid ({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

1-(2,5-difluoro-phenyl)-cyclopropanecarboxylic acid ({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

1-(4-chloro-phenyl)-cyclopropanecarboxylic acid ({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

2-(4-fluoro-phenyl)- *N* -({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-acetamide;

(3,5-bistrifluoromethyl-phenyl)- *N* -({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-acetamide;

(3,4-dichlorophenyl)- *N* -({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-acetamide;

1-(2,5-difluorophenyl)-cyclopropanecarboxylic acid ({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

(2,5-difluorophenyl)- *N* -({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-acetamide;

(3,4-dichlorophenyl)- *N* -({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-acetamide;

1-(2,5-difluorophenyl)-cyclopropanecarboxylic acid ({[2-(5-ethanesulfonyl-2-methoxy-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

(2,5-difluorophenyl)- *N* -({[2-(5-ethanesulfonyl-2-methoxy-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-acetamide;

1-(3,4-dichlorophenyl)-cyclopropanecarboxylic acid ({[2-(5-ethanesulfonyl-2-methoxy-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

3,4-dichlorophenyl- *N* -({[2-(5-ethanesulfonyl-2-methoxy-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-acetamide;

1-(2,5-difluorophenyl)-cyclopropanecarboxylic acid (methyl-{methyl-[2-(4-methyl-3-sulfamoyl-phenylamino)-pyrimidin-4-yl]-amino}-1H-benzoimidazol-2-yl)-amide;

1-(3,4-dichlorophenyl)-cyclopropanecarboxylic acid (methyl-{methyl-[2-(4-methyl-3-sulfamoyl-phenylamino)-pyrimidin-4-yl]-amino}-1H-benzoimidazol-2-yl)-amide;

(3,4-dichlorophenyl)-N-(methyl-{methyl-[2-(4-methyl-3-sulfamoyl-phenylamino)-pyrimidin-4-yl]-amino}-1H-benzoimidazol-2-yl)-acetamide;

2-(2,3-dimethoxyphenyl)-N-(5-{[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-1-methyl-1H-benzoimidazol-2-yl)-acetamide;

2-(2-methoxyphenyl)-N-(5-{[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-1-methyl-1H-benzoimidazol-2-yl)-acetamide;

2-(3-methoxyphenyl)-N-(5-{[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-1-methyl-1H-benzoimidazol-2-yl)-acetamide;

2-(3-methoxyphenyl)-N-(5-{[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-1-methyl-1H-benzoimidazol-2-yl)-acetamide;

2-(2-fluorophenyl)-N-([2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-acetamide;

2-(3-fluorophenyl)-N-([2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-acetamide;

(2,5-difluorophenyl)-N-([2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-acetamide;

(2,3-difluorophenyl)-N-([2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-acetamide;

2-(3,4-dimethoxyphenyl)-N-(5-{[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-1-methyl-1H-benzoimidazol-2-yl)-acetamide;

(2,5-difluorophenyl)-N-(methyl-{methyl-[2-(4-methyl-3-sulfamoyl-phenylamino)-pyrimidin-4-yl]-amino}-1H-benzoimidazol-2-yl)-acetamide;

1-(3,4-dichloro-phenyl)-cyclopropanecarboxylic acid ({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

2-(2-chlorophenyl)-N-([2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-acetamide;

2-(3-chlorophenyl)- *N*-({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-acetamide;

2-(4-chlorophenyl)- *N*-({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-acetamide;

2-(3,5-dimethoxyphenyl)- *N*-(5-{[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-1-methyl-1H-benzoimidazol-2-yl)-acetamide;

2-(2,5-dimethoxyphenyl)- *N*-(5-{[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-1-methyl-1H-benzoimidazol-2-yl)-acetamide;

(2,5-dichlorophenyl)- *N*-({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-acetamide;

N-({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-methyl-C-phenyl-butyramide;

(3,5-dimethylphenyl)- *N*-({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-acetamide;

N-({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)- phenyl-isobutyramide; and

benzo[1,3]dioxol-5-yl-*N*-({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-acetamide;

or a salt, solvate, or physiologically functional derivative thereof.

31. A pharmaceutical composition, comprising: a therapeutically effective amount of a compound as claimed in any one of claims 1 to 30, or a salt, solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

32. The pharmaceutical composition of claim 31, further comprising at least one additional anti-neoplastic agent.

33. The pharmaceutical composition of claim 31, further comprising an additional agent which inhibits angiogenesis.

34. A method of treating a disorder in a mammal, said disorder being mediated by at least one of inappropriate TIE-2 and VEGFR-2 activity, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in any one of claims 1 to 30, or a salt, solvate, or a physiologically functional derivative thereof.
35. The method of claim 34, wherein the disorder is cancer.
36. A compound as claimed in any of claims 1 to 30, or a salt, solvate, or a physiologically functional derivative thereof for use in therapy.
37. Use of a compound as claimed in any of claims 1 to 30, or a salt, solvate, or a physiologically functional derivative thereof in the preparation of a medicament for use in the treatment of a disorder mediated by at least one of inappropriate TIE-2 and VEGFR-2 activity.
38. The use of claim 37, wherein the disorder is cancer.
39. A method of treating cancer in a mammal, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in any one of claims 1 to 30, or a salt, solvate, or a physiologically functional derivative thereof.
40. The method of claim 39, further comprising administering a therapeutically effective amount of at least one additional anti-cancer therapy.
41. The method of claim 40, wherein the additional anti-cancer therapy is administered concomitantly with the administration of the compound, salt, solvate or physiologically functional derivative as claimed in any one of claims 1 to 30.
42. The method of claim 40, wherein the additional anti-cancer therapy is administered after the administration of the compound, salt, solvate or physiologically functional derivative as claimed in any one of claims 1 to 30.

43. The method of claim 40, wherein the additional anti-cancer therapy is administered before the administration of the compound, salt, solvate or physiologically functional derivative as claimed in any one of claims 1 to 30.

44. A method of treating a disorder in a mammal, said disorder being mediated by at least one of inappropriate TIE-2 and VEGFR-2 activity, comprising: administering to said mammal therapeutically effective amounts of (i) a compound as claimed in any one of claims 1 to 30, or a salt, solvate or physiologically functional derivative thereof and (ii) an agent to inhibit growth factor receptor function.

45. The method of claim 44, wherein the agent to inhibit growth factor receptor function inhibits the function of platelet derived growth factor receptor.

46. The method of claim 44, wherein the agent to inhibit growth factor receptor function inhibits the function of epidermal growth factor receptor.

47. The method of claim 44, wherein the agent to inhibit growth factor receptor function inhibits the function of the erbB2 receptor.

48. The method of claim 44, wherein the agent to inhibit growth factor receptor function inhibits the function of a VEGF receptor.

49. The method of claim 44, wherein the agent to inhibit growth factor receptor function inhibits the function of the TIE-2 receptor.

50. The method of claim 44, wherein the agent to inhibit growth factor receptor function inhibits the function of the epidermal growth factor receptor and erbB2.

51. The method of claim 44, wherein the agent to inhibit growth factor receptor function inhibits the function of at least two of the epidermal growth factor receptor, erbB2, and erbB4.

52. The method of claim 44, wherein the agent to inhibit growth factor receptor function inhibits the function of the VEGF receptor and the TIE-2 receptor.
53. The method of claim 44, wherein the disorder is cancer.
54. A method of treating a disorder in a mammal, said disorder being characterized by inappropriate angiogenesis, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in any one of claims 1 to 30, or a salt, solvate or physiologically functional derivative thereof.
55. The method of claim 54, wherein the inappropriate angiogenesis results from at least one of inappropriate VEGFR1, VEGFR2, VEGFR3 or TIE-2 activity.
56. The method of claim 54, wherein the inappropriate angiogenesis results from inappropriate VEGFR2 and TIE-2 activity.
57. The method of claim 54, further comprising administering a therapeutically effective amount of a VEGFR2 inhibitor.
58. The method of claim 54, wherein the compound as claimed in any one of claims 1 to 17 inhibits TIE-2 and VEGFR-2 activity.
59. The method of claim 54, wherein the disorder is cancer.
60. Use of a compound as claimed in any of claims 1 to 30, or a salt, solvate, or a physiologically functional derivative thereof in the preparation of a medicament for use in the treatment of a disorder characterized by inappropriate angiogenesis.